Compare PLETHICO PHARMA with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA WYETH LTD PLETHICO PHARMA/
WYETH LTD
 
P/E (TTM) x -1.1 27.7 - View Chart
P/BV x 0.0 5.3 0.3% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 PLETHICO PHARMA   WYETH LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
WYETH LTD
Mar-13
PLETHICO PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs3951,044 37.8%   
Low Rs31818 3.8%   
Sales per share (Unadj.) Rs604.4298.6 202.4%  
Earnings per share (Unadj.) Rs32.557.2 56.7%  
Cash flow per share (Unadj.) Rs51.358.4 87.9%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs473.6249.5 189.8%  
Shares outstanding (eoy) m34.0822.72 150.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.1 11.3%   
Avg P/E ratio x6.616.3 40.3%  
P/CF ratio (eoy) x4.215.9 26.0%  
Price / Book Value ratio x0.53.7 12.1%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m7,26221,157 34.3%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m1,596400 399.0%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m20,5986,783 303.7%  
Other income Rs m386353 109.6%   
Total revenues Rs m20,9847,136 294.1%   
Gross profit Rs m2,8181,617 174.2%  
Depreciation Rs m64227 2,414.7%   
Interest Rs m1,5936 28,967.3%   
Profit before tax Rs m9691,938 50.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m-138632 -21.9%   
Profit after tax Rs m1,1071,301 85.1%  
Gross profit margin %13.723.8 57.4%  
Effective tax rate %-14.332.6 -43.8%   
Net profit margin %5.419.2 28.0%  
BALANCE SHEET DATA
Current assets Rs m18,8776,984 270.3%   
Current liabilities Rs m11,8962,056 578.6%   
Net working cap to sales %33.972.6 46.6%  
Current ratio x1.63.4 46.7%  
Inventory Days Days3699 36.2%  
Debtors Days Days19824 826.4%  
Net fixed assets Rs m9,861244 4,036.2%   
Share capital Rs m341227 150.0%   
"Free" reserves Rs m12,3315,441 226.6%   
Net worth Rs m16,1395,668 284.7%   
Long term debt Rs m4,70625 18,823.2%   
Total assets Rs m33,1467,901 419.5%  
Interest coverage x1.6353.3 0.5%   
Debt to equity ratio x0.30 6,610.9%  
Sales to assets ratio x0.60.9 72.4%   
Return on assets %8.116.5 49.3%  
Return on equity %6.922.9 29.9%  
Return on capital %12.334.0 36.1%  
Exports to sales %21.40.2 9,796.0%   
Imports to sales %15.236.3 41.9%   
Exports (fob) Rs m4,40215 29,745.9%   
Imports (cif) Rs m3,1362,465 127.2%   
Fx inflow Rs m4,40215 28,963.2%   
Fx outflow Rs m3,1842,677 118.9%   
Net fx Rs m1,219-2,662 -45.8%   
CASH FLOW
From Operations Rs m2,437923 264.0%  
From Investments Rs m-6,265317 -1,976.9%  
From Financial Activity Rs m2,490-481 -517.7%  
Net Cashflow Rs m-1,337759 -176.2%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 4.3 11.3 38.1%  
FIIs % 5.5 7.2 76.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 30.4 24.7%  
Shareholders   10,665 21,978 48.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   PANACEA BIOTECH  BIOCON   FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS